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A variable fraction of anaplastic large-cell lymphomas (AL-
CLs) exhibits a t(2;5)(p23;q35) translocation that results in
expression of the chimeric hyperphosphorylated protein
NPM-ALK (p80). Tumor cells expressing NPM-ALK exhibit
markedly enhanced proliferative activity, but comparative
cellular kinetic studies on ALK1 (ALK lymphomas) and ALK–
lymphomas are lacking. The present study showed that
ALK1 lymphomas, detected with the monoclonal antibody
ALKc (n 5 17), had significantly higher average values for the
proliferation-associated parameters mitotic index, ana/telo-
phase index, growth index (x 3 mitotic index – apoptotic
index, assuming x 5 3), percentages of Ki-671 cells and frac-
tion of cells expressing cyclin A or B or the cell cycle–regu-
latory protein p34cdc2 than did ALK– ALCLs (n 5 15).
Whether this intense proliferative activity contributes to the
good response to chemotherapy and favorable outcome of
ALK1 ALCLs remains to be assessed in a larger series of
patients. Our findings support the notion that ALK1 and
ALK– ALCLs are 2 distinct disease entities. Int. J. Cancer 86:
777–781, 2000.
© 2000 Wiley-Liss, Inc.
Long after their first description in 1985 (Stein et al., 1985),
Ki-1 (CD30)1 anaplastic large cell lymphomas (ALCLs) have
remained a subject of controversy. This pertains not only to the
origin of tumor cells, mostly T or null type, but also to ALCLs as
a single entity and their subdivision into morphologically distinct
subtypes (Kadin, 1997).
A major breakthrough occurred when it was recognized that
ALCL tumor cells in 30% to 40% of cases exhibit a specific
recurrent translocation, t(2;5)(p23; q35) (Le Beau et al., 1988).
This chromosomal aberration causes the novel tyrosine kinase
ALK (anaplastic lymphoma kinase) gene (on chromosome 2) to
fuse with the nucleophosmin (NPM) gene (on chromosome 5),
which encodes a nuclear phosphoprotein (B23 or numatrin) shut-
tling between nucleus and cytoplasm. The resulting fusion gene
encodes a chimeric protein, NPM–ALK (p80), consisting of the
N-terminal portion of NPM fused to the entire cytoplasmic domain
of ALK (Morris et al., 1994).
The presence of NPM–ALK chimeric transcripts or proteins can
be detected in ALCL samples by RT-PCR. Taking advantage of
the fact that the ALK protein is not expressed in non-neoplastic
lympho-hemopoietic tissues, immunostaining with polyclonal
(Shiota et al., 1994) and monoclonal (Pulford et al., 1997; Falini et
al., 1998) antibodies (MAbs) specific for the cytoplasmic portion
of ALK has been widely applied to provide evidence for the t(2;5)
translocation (Falini et al., 1998). MAbs directed against the ALK
protein and the N-terminal portion of NPM (Cordell et al., 1999)
have been used in combination to distinguish between ALCLs
bearing the NPM–ALK fusion protein (about 85% of cases) and
those expressing variant ALK fusion proteins (about 15% of
cases). The distinction between ALK1 lymphomas (bearing NPM-
ALK or ALK-variant fusion proteins) and ALK– ALCLs appears
to be clinically important because of the apparently better prog-
nosis of the former condition (Falini et al., 1999).
It has long been understood and theoretically documented that
the success of chemotherapy and radiotherapy in the treatment of
malignant neoplasms depends to a great extent upon their cellular
kinetic properties. To the best of our knowledge, differences in the
growth rate of ALK1 and ALK-negative ALCLs have so far not
been reported. The present study was designed to provide some of
this information. Since the combined use of several proliferation-
associated parameters to separate groups may be superior to using
any single variable (Leoncini et al., 1999), we assessed not only
the mitotic index (MI) and the percentage of Ki-671 cells but also
the fraction of cells expressing cyclin A or B or the cell cycle–
regulatory protein p34cdc2 (abbreviated as p34). The ana/telophase
indices (ATI; Leoncini et al., 1998) were registered because in
Hodgkin’s disease, another large group of CD301 malignant lym-
phomas, many mitoses are not successful in terms of cell produc-
tion (Spina et al., 1996). Since growth equals cell production
minus cell deletion (Spina et al., 1997), we also established, in
each case, the apoptotic index (AI).
MATERIAL AND METHODS
Case selection and conventional
histology/immuno-histochemistry
Paraffin blocks from a total of 32 ALCLs were collected from
the files of our institutions in Sassari, Bologna and Siena.
Biopsy specimens were sliced and fixed in a neutral, buffered,
4% aqueous formaldehyde solution and processed for conven-
tional histology, as reported previously (Leoncini et al., 1998).
The various lymphomas were accepted based on the following
criteria: no treatment prior to diagnosis, adequate fixation of
biopsy material, sufficient amounts of tissue in paraffin blocks,
absence of large areas of necrosis and satisfactory clinical data
(response to therapy and status at the end of 1998). For the
qualitative histologic evaluation, 4 mm-thick sections were
stained with hemalum– eosin, Giemsa, periodic acid Schiff
(PAS) reagent, Mallory trichrome and Gomori’s silver impreg-
nation. For enhanced antigen retrieval, sections were treated
with microwaves (Cattoretti et al., 1993) or boiled in a 10 mM
citrate buffer, pH 6, for 10 min. Sections to be immunostained
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for ALK protein were subjected to microwave heating (750 W
for 3 cycles of 5 min each) in 1 mM EDTA buffer, pH 8.0, as
previously described (Falini et al., 1998). Standard immuno-
phenotyping was carried out using a large panel of antibodies,
commonly applied in our institutions to the evaluation of ma-
lignant lymphomas, and the APAAP and/or the EnVision11
system (Sabattini et al., 1998). Cases were separated into 2
groups, depending on the positive (ALKc1) or negative
(ALKc–) immuno-histochemical reaction of neoplastic cells to
the ALKc MAb (see below). Immunomorphologic criteria for
ALCL were those originally established by Stein et al. (1985)
and defined in subsequent reports on subtypes of this lymphoma
(Falini et al., 1997; Kadin, 1997). The first diagnosis was made
independently by at least 2 experienced pathologists (LL, SP).
After immunostaining with the ALKc antibody, a second, com-
mon review reached a consensus on 3 controversial cases. The
morphologic, immunophenotypic and clinical features of the 32
cases of ALCL investigated in this study are summarized in
Table I.
Antibodies used for quantitative immunohistology
The mouse MAb ALKc, which is directed against the cytoplas-
mic portion of the ALK protein (Falini et al., 1998), was generated
in the laboratory of one of the authors (BF). In our hands, this
reagent gave stronger immunolabeling of tumor cells (especially
nuclei) than the mouse MAb ALK1 (Dako, Milan, Italy) or the
goat polyclonal anti-ALK anti-serum (Santa Cruz Biotechnology,
Santa Cruz, CA), so we chose it for our immuno-histochemical
studies. The mouse MAbs anti-p34cdc2 serine/threonine kinase/cdk
AB-1 (clone A17.1.1), for the detection of p34, and anti-cyclin B-1
AB-1 (clone V152), for that of cyclin B, were purchased from
Neomarkers (Fremont, CA, U.S.A.). The anti-cyclin A MAb was
generated by one of us (AG). We applied the mouse MAb MIB-1
(anti-Ki-67; Immunotech, Marseille, France) to detect the prolif-
eration-associated antigen Ki-67. Immunostained cells were reg-
istered as positive, irrespective of the localization of the reaction
product (nucleus-restricted, cytoplasm-restricted or nuclear and
cytoplasmic).
Cell counts and estimates of growth index
Cell counts were carried out as described before (Leoncini et al.,
1996, 1998). In a first step, the mean numbers per case of CD301
and CD30– lymphoid cells per high-power field [HPF; 56,000
mm2, examined with an oil immersion objective (1003)] were
registered in 20 HPFs chosen at random. In the entire section
(.100 HPF), CD301 cells in individual phases (pro-, meta-, ana-
and telophases) of mitosis were then assessed as percentages of the
total number of CD301 cells and expressed as MI (all mitotic
phases) or as ATI (only ana- and telophases). Similarly, we also
established, in each case, the AI (Spina et al., 1997). Neoplastic
cells immunostained by any one of the above antibodies were
counted and the numbers registered as percentages of CD301
cells. Intra- and inter-observer correlations, assessed by compari-
son of separate counts on the same section but different HPFs of a
number of cases by 2 independent pathologists, were significant
(r $ 0.95, p 5 0.01). Since mitotic and apoptotic times (duration)
in each case are unknown but growth equals cell production minus
cell deletion, we estimated the growth index (GI) by assuming the
value 3 for x (GI 5 x 3 MI – AI) (Spina et al., 1997).
Statistical analysis
To evaluate univariately the significance level indicating that the
2 independent samples of patients with ALK1 and ALK– ALCLs
were generated from different populations, the Wilcoxon rank sum
test was used.
The statistical significance of the linear correlation coefficient
between pairs of variables was tested and the corresponding re-
gression analysis outlined. For the same variables, ALK1 and
ALK– ALCL groups were compared both univariately and biva-
riately by computing the Hotelling T2 and the related F-statistic
values (Krzanowski, 1988).
A stepwise linear discriminant analysis was then applied to a
wider set of measured variables, to seek the subset of variables that
would allow the best multivariate, statistically significant distinc-
tion between the 2 groups. To select variables and stop the step-
wise procedure, the Wilks l criterion and the associated F statistic
were used. Group classifications were evaluated with a jack-knifed
classification matrix.
Data analysis was carried out by means of the BMDP statistical
software and the statistical toolbox of the MATLAB package.
RESULTS
Qualitative histologic and immuno-histochemical findings
The MAb ALKc gave strong cytoplasmic and nuclear labeling
of tumor cells, suggestive of the presence of NPM–ALK, in 17 of
the 32 ALCL cases studied (Fig. 1). No labeling of obviously
non-neoplastic elements was observed in any of the tissue samples
investigated, thus confirming previous observations by Falini et al.
(1998). The immunostaining pattern of the MAbs directed against
p34, cyclins A and B and Ki-67 corresponded to that observed in
other non-Hodgkin’s lymphomas (Leoncini et al., 1999). Identifi-
cation of various mitotic phases and of apoptotic cells/bodies
caused no difficulties (Spina et al., 1996).
MI plotted against ATI
The scattergram shown in Figure 2 resulted from a plot of MI
per case against ATI per case. It documents a highly significant
positive linear correlation between these 2 variables (r 5 0.883,
p , 0.0001), so the regression line fits the data well. The values for
MI and ATI, substantially higher in ALK1 than in ALK– ALCLs,
are also clearly visible in Figure 2. On the basis of these variables,
TABLE I – ALCLS STUDIED1
ALKc1 ALCL ALKc2 ALCL
Number of cases 17 15
Age of patients [range
and median (years)]
10–57 (21) 10–83 (60)
Female:male ratio 9:8 9:6
Cell line
T 5 5
Null 12 10
Histologic subtype
Common 14 12
Small-cell 2 —
Large-cell 1 2
Hodgkin’s-like — 1
Localization
Lymph node 15 12
Tonsil 1 —
Breast 1 —
Skin — 14
Pharynx — 1
Colon — 1
Stage
I 1 1
II 9 6
III 5 6
IV 2 2
Response to therapy2
Complete remission 15 4
Relapse 2 11
Outcome3
Alive 16 8
Dead 1 7
1If not stated otherwise, the values correspond to numbers of cases.–
2Chemotherapy consisted of COP, 2 3 COPADM and 4 3 VEBBP/
Sequence 1 (Brugie`res et al., 1998).–3Outcome refers to 1.1.1999, i.e.,
up to 9 years after diagnosis.–4This patient also had retroperitoneal
lymph node involvement.
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both univariate and bivariate tests pointed out a highly significant
difference between the 2 groups of lymphomas (p , 0.001).
Comparison of ALK1 and ALK– ALCLs with regard to the
proliferation-associated variables GI, % p341 cells and %
MIB-11 cells
All 3 proliferation-associated variables gave values that were
markedly higher in ALK1 than in ALK– ALCLs. The Wilcoxon
rank sum test documented that the statistical significance of the
difference between the 2 groups was greatest for GI (p , 0.001)
but also proved to be very impressive for the percentages of
MIB-11 cells (p , 0.001) and of p341 cells (p , 0.001). How-
ever, a considerable overlap can be seen in all 3 graphs of Figure
3, so simple evaluation of individual values for each of these
parameters, taken alone, does not allow for a distinction between
ALK1 and ALK– ALCLs.
Correlations between expression of cyclins A and B and the
percentages of MIB-11 cells and the MI, respectively
As visualized in Figure 4a, the percentages of MIB-11 cells
correlated well with those of cyclin A1 cells in a positive linear
fashion (r 5 0.691, p , 0.001). Almost equally good was the
linear correlation between the MI and the fractions of cyclin B1
cells (r 5 0.661, p , 0.001; Fig. 4b). Similarly significant, though
in part somewhat loose, correlations existed between the values for
each of the other proliferation-associated variables (details not
shown). Figure 4 further illustrates the markedly higher values for
the percentages of cyclin A1 and cyclin B1 cells in ALKc1 than
in ALKc– ALCLs (p , 0.001). Hotelling’s T2 for both the per-
centages of cyclin A1 cells against MIB-11 cells and the percent-
ages of cyclin B1 cells against MI supplied a high statistical
significance, also in the bivariategroup comparison (p , 0.001).
FIGURE 3 – Significantly higher values for the 3 proliferation-asso-
ciated parameters GI (5 3 3 MI – AI) (a), % p341 cells (b) and %
Ki-67 (MIB-1)1 (c) cells per case in ALKc1 than in ALKc– ALCLs
(see legend to Fig. 2; medians are indicated by bars).
FIGURE 1 – Paraffin sections of ALCLs immunostained with the
ALKc MAb, showing positively reacting large atypical cells, mitosis
(a) and an apoptotic body (b) [EnVision11 technique (Sabattini et al.,
1998)]. Scale bar 5 25 mm.
FIGURE 2 – Comparison of MI (%) and ATI (%) per case of ALKc–
(open circles) and ALKc1 (closed circles) ALCLs, illustrating the
significant difference and the correlation between the 2 (line is a
regression line).
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Discriminant analysis of proliferation-associated variables as to
their power to distinguish ALK1 and ALK– ALCLs
Although we deal here with a limited number of cases and the
results should, therefore, at best be taken as preliminary, it was of
interest to carry out this analysis as it might suggest a certain order
of correlations between individual proliferation-associated param-
eters and ALK positivity. It was not meant for diagnostic purposes.
All proliferation-associated variables, i.e., GI, MI, ATI, AI, %
cyclin A1 cells, % cyclin B1 cells, % p341 cells and % MIB-11
cells, were submitted to a stepwise linear discriminant analysis.
After step 3, the entered variables were (values for Wilks’ l and
associated F values in parentheses): GI (l 5 0.336, F 5 16.1), %
cyclin B1 cells (l 5 0.269, F 5 6.50) and % p341 cells (l 5
0.243, F 5 2.68). However, since GI is based on an assumption
(x 5 3), this variable could not be used for factual calculations.
Without using the GI as a parameter, the results of the stepwise
discriminant analysis did not change significantly when MI was
substituted for GI.
Classification results indicated that all ALK– ALCLs (100%)
were, based on the present variables, correctly classified, while
only 1 (5.9%) of the 17 ALK1 ALCLs was misclassified. This
amounts to a total percent of cases correctly classified of 97.2%.
DISCUSSION
The main finding of the present study was the markedly higher
values for proliferation-associated variables in ALK1 than in
ALK– ALCLs. This pertains not only to MI and ATI (Fig. 2) but
also to GI and the percentages of p341 and MIB-11 cells (Fig. 3)
as well as the fractions of cyclin A1 and cyclin B1 cells (Fig. 4).
While all ALCLs taken together already belong to the non-
Hodgkin’s lymphomas with the highest proliferative activity (Le-
oncini et al., 1999), our study identified the ALK1 subgroup of
these neoplasms as even more intensely cycling. Also, our results
give no indication that the high rate of cell production in ALK1
ALCLs is counterbalanced by an excessive rate of apoptotic cell
death. In a previous report (Spina et al., 1997), growth was
estimated by GI 5 x 3 MI – AI in 94 non-Hodgkin’s lymphomas
of various types, and the assumed value x 5 3 reflects a situation
where GI touches the zero line but does not become negative.
Another finding that we consider important lies in the rather
close correlations between the values for distinct proliferation-
associated variables. The strong positive linear relationship be-
tween MI and ATI (Fig. 2) favors the notion that in ALCLs most
cell divisions are successful, in contrast to Hodgkin’s disease,
where many mitoses become arrested in metaphase and may end
up in cell death (Leoncini et al., 1996; Spina et al., 1996). The
correlations between % MIB-11 cells and % cyclin A1 cells and
between MI and the fraction of cyclin B1 (the mitotic cyclin) cells
(Fig. 4) support the view that most processes involved in the
cell-cycle machinery are up-regulated in ALK1 compared to
ALK– ALCLs. This is in line with experimental findings that
expression of cDNAs encoding NPM–ALK (p80) in rat 1a fibro-
blasts induced accelerated cell-cycle entry into S phase, marked
up-regulation of cyclin A and cyclin D1 expression and enhance-
ment of AP-1–dependent transcriptional activation. In addition,
markedly elevated expression of several immediate-early genes
involved in cellular proliferation (e.g., fos, jun and c-myc) was
noted (Wellmann et al., 1997).
As alluded to under Results, ALK positivity may not correlate
equally well with individual proliferation-associated parameters.
More extended studies are needed to clarify this point.
Other observations made in our study confirm earlier reports of
others on ALCLs expressing the NPM–ALK chimeric protein,
e.g., the younger age of patients, the frequency of the T- or null
cell lines, the wide morphologic spectrum and the more favorable
response to chemotherapy (Falini et al., 1999) in ALK1 vs. ALK–
lymphomas.
The molecular background of the intense proliferative activity in
ALK1 ALCLs has not been fully clarified. ALK, a novel receptor
that exhibits a close relationship to leukocyte tyrosine kinases, is
normally expressed by certain cells of the nervous system but not
in the non-neoplastic lymphoid/hemopoietic tissue (Iwahara et al.,
1997; Morris et al., 1997). The t(2;5) translocation brings the
portion of the gene encoding the intracellular portion of ALK
under the control of the strong NPM gene promoter, which leads
to its ectopic expression in lymphoid cells and the resultant dys-
regulated growth (Morris et al., 1994). The NPM portion of the
fusion protein provides an oligomerization motif that promotes a
self-association of NPM–ALK and results in its constitutive acti-
vation (Rodriguez and Park, 1994). The signaling pathway(s)
leading to the mitogenic effect appears to involve the phosphory-
lation of target molecules. It has been shown, e.g., that NPM–ALK
forms a complex with phospholipase Cg, which leads to tyrosine
phosphorylation and activation of this enzyme (Bai et al., 1998).
In conclusion, we have shown that the values for proliferation-
associated parameters (MI, ATI, GI, % p341 cells, % cyclin B1
cells and % MIB-11 cells) were markedly higher in ALK1 than in
ALK– ALCLs. This finding suggests that these are 2 distinct
disease entities. Whether the high mitotic activity of ALK1 com-
pared to ALK– ALCLs correlates with a better outcome (Tilly et
al., 1997) remains to be assessed in larger clinical studies. The
same pertains to the problem of multidrug resistance (Miller et al.,
1996).
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